Education
About Us
Working with TipRanks
Follow Us
Medigene AG (GB:0QGJ)
LSE:0QGJ
0QGJ Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.12 - €3.67
Previous CloseN/A
Volume15.00
Average Volume (3M)10.23K
Market Cap
€2.83M
Enterprise ValueN/A
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta2.28
Next Earnings
May 14, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding14,887,594
10 Day Avg. Volume29,298
30 Day Avg. Volume10,231
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.40
Price to Cash Flow (P/CF)3.70
P/FCF Ratio4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.00Price Target Upside900.00% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Medigene News
PremiumCompany Announcements
Medigene AG to File for Insolvency Amid Financial Challenges
PremiumCompany Announcements
Medigene AG Reports Significant Share Capital Loss and Cash Runway Adjustment
PremiumCompany Announcements
Medigene AG Updates Total Voting Rights to 14.9 Million
PremiumCompany Announcements
Medigene AG Advances with Equity Agreement to Boost CapitalPremiumCompany Announcements
Medigene AG Adjusts 2024 Financial Guidance Amid Milestone Payment Delay---
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe company's cash runway guidance has been extended to July 2025, driven by cost reductions.
InnovationMDG1015 will be manufactured with a short, 6-day cell expansion period, leading to optimized cells with potential for improved clinical results including efficacy, durability, and safety.
PartnershipsMedigene announced a co-development partnership with EpimAb Biotherapeutics to advance off-the-shelf T cell receptor-guided T Cell Engagers for immune-related disorders.
Bears Say
Clinical TrialsFactors which could impede reaching the price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding.
InsolvencyThe company announced that it is filing to open insolvency proceedings with local courts in Germany.
Workforce ReductionMedigene plans a 40% reduction in its current workforce, effective 2025, alongside other cost-saving initiatives.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
<0.01%
Mutual Funds
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
0QGJ FAQ
What was Medigene AG’s price range in the past 12 months?
Medigene AG lowest share price was €0.12 and its highest was €3.67 in the past 12 months.
What is Medigene AG’s market cap?
Medigene AG’s market cap is €2.83M.
When is Medigene AG’s upcoming earnings report date?
Medigene AG’s upcoming earnings report date is May 14, 2025 which is in 26 days.
How were Medigene AG’s earnings last quarter?
Currently, no data Available
Is Medigene AG overvalued?
According to Wall Street analysts Medigene AG’s price is currently Undervalued.
Does Medigene AG pay dividends?
Medigene AG does not currently pay dividends.
What is Medigene AG’s EPS estimate?
Medigene AG’s EPS estimate is -0.38.
How many shares outstanding does Medigene AG have?
Medigene AG has 14,887,594 shares outstanding.
What happened to Medigene AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medigene AG?
Currently, no hedge funds are holding shares in GB:0QGJ
---
Medigene Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.00 (900.00% Upside)
€2.00 (900.00% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.04%
12-Months-Change
Fundamentals
Return on Equity
-63.93%
Trailing 12-Months
Asset Growth
-31.69%
Trailing 12-Months
Company Description
Medigene AG
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
---
0QGJ Stock 12 Month Forecast
Average Price Target
€2.00
▲(900.00% Upside)
Technical Analysis
Qiagen
―
Evotec
―
Fresenius Medical Care AG & Co. KGaA
―
Porsche Automobil Holding
―
Sartorius
―
Best Analysts Covering 0QGJ
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-59.06%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -59.06% per trade.
---